1. Patients with history of HIV/HCV/HBV positive or immunocompromised or TB <br/ >2. Patients with significant co-morbidities at screening, as judged by the treating Investigator <br/ >3. Moribund state in which death is perceived to be imminent (â?¤48 hours) <br/ >4. Known hypersensitivity to any component of the investigational product <br/ >5. Pregnant or nursing (lactating) women. <br/ >6. Suspected uncontrolled bacterial, fungal, viral, or other infection (besides COVID-19). <br/ >7. Patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs/convalescent plasma (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). <br/ >8. Participation in any other clinical study

1. Patients with history of HIV/HCV/HBV positive or immunocompromised or TB <br/ >2. Patients with significant co-morbidities at screening, as judged by the treating Investigator <br/ >3. Moribund state in which death is perceived to be imminent (â?¤48 hours) <br/ >4. Known hypersensitivity to any component of the investigational product <br/ >5. Pregnant or nursing (lactating) women. <br/ >6. Suspected uncontrolled bacterial, fungal, viral, or other infection (besides COVID-19). <br/ >7. Patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs/convalescent plasma (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). <br/ >8. Participation in any other clinical study

N/A

N/A

1. Patients with history of HIV/HCV/HBV positive or immunocompromised or TB <br/ >2. Patients with significant co-morbidities at screening, as judged by the treating Investigator <br/ >3. Moribund state in which death is perceived to be imminent (â?¤48 hours) <br/ >4. Known hypersensitivity to any component of the investigational product <br/ >5. Pregnant or nursing (lactating) women. <br/ >6. Suspected uncontrolled bacterial, fungal, viral, or other infection (besides COVID-19). <br/ >7. Patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs/convalescent plasma (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). <br/ >8. Participation in any other clinical study

1. Patients with history of HIV/HCV/HBV positive or immunocompromised or TB <br/ >2. Patients with significant co-morbidities at screening, as judged by the treating Investigator <br/ >3. Moribund state in which death is perceived to be imminent (â?¤48 hours) <br/ >4. Known hypersensitivity to any component of the investigational product <br/ >5. Pregnant or nursing (lactating) women. <br/ >6. Suspected uncontrolled bacterial, fungal, viral, or other infection (besides COVID-19). <br/ >7. Patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs/convalescent plasma (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra). <br/ >8. Participation in any other clinical study